Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Acer Therapeutics Inc. (ACER) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update OLPRUVA™ kits now available in all dosage strengths and ready to ship to patients NEWTON, MA – August 14, 2023 – Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The second quarter of 2023 marked continued progress for Acer as we execute on our OLPRUVA™ launch strategy,” said Chris Schelling, CEO and Founder of Acer. “We are pleased to offer OLPRUVA™ in the U.S. to certain UCD patients as a novel alternative o..."
06/07/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON, MA – May 15, 2023 – Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The first quarter of 2023 was marked by considerable progress and a number of significant milestones in support of our commercial launch of OLPRUVA™, an innovative treatment option for patients with certain Urea Cycle Disorders ,” said Chris Schellin..."
05/01/2023 8-K Quarterly results
04/27/2023 424B2 Form 424B2 - Prospectus [Rule 424(b)(2)]:
04/27/2023 8-K Quarterly results
04/14/2023 ARS Form ARS - Annual Report to Security Holders:
04/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Quarterly results
03/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/22/2023 8-K Credit agreement amendment
Docs: "Form of Pre-Funded Common Stock Purchase Warrant",
"Form of Common Stock Purchase Warrant",
"Opinion of Pillsbury Winthrop Shaw Pittman LLP",
"Form of Securities Purchase Agreement, between Acer Therapeutics Inc. and the Purchaser",
"Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEWTON, MA - March 22, 2023 - Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company's common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 2,920,306 shares of common stock. The warrants will have an exercise price of $0.7..."
03/22/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acer Therapeutics Announces Topline Results from ACER-801 Phase 2a Trial ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women"
03/16/2023 4 Quartel Adrian W (Chief Medical Officer) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 30,000 options to buy @ $1.67, valued at $50.1k
03/16/2023 4 Paul Bernard H (Chief People Officer) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 30,000 options to buy @ $1.67, valued at $50.1k
03/16/2023 4 PALMIN HARRY S (CFO) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 30,000 options to buy @ $1.67, valued at $50.1k
03/16/2023 4 Klopp John Michael (Chief Technical Officer) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 30,000 options to buy @ $1.67, valued at $50.1k
03/16/2023 4 Joseph Donald (Chief Legal Officer and Secy) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 30,000 options to buy @ $1.67, valued at $50.1k
03/16/2023 4 Hayden Tanya (COO) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 30,000 options to buy @ $1.67, valued at $50.1k
03/16/2023 4 GRIFFIN MICHELLE RENEE (Director) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 20,000 options to buy @ $1.67, valued at $33.4k
03/16/2023 4 DUNN JOHN MICHAEL (Director) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 20,000 options to buy @ $1.67, valued at $33.4k
03/16/2023 4 Davis Jefferson E (Chief Business Officer) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 30,000 options to buy @ $1.67, valued at $50.1k
03/16/2023 4 ASELAGE STEVE (Director) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 20,000 options to buy @ $1.67, valued at $33.4k
03/16/2023 4 Amello Jason (Director) has filed a Form 4 on Acer Therapeutics Inc.
Txns: Granted 20,000 options to buy @ $1.67, valued at $33.4k
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update Results to be presented from a survey designed to quantify treatment preferences of healthcare providers for Urea Cycle Disorders"
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 7.5% stake in Acer Therapeutics Inc.
02/13/2023 8-K Quarterly results
02/07/2023 424B2 Form 424B2 - Prospectus [Rule 424(b)(2)]:
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Pillsbury Winthrop Shaw Pittman LLP",
"Opinion of Pillsbury Winthrop Shaw Pittman LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy